EU Court Advisor Backs Google's $4.7 Billion Android Fine

Alphabet's Google suffered a setback in its yearslong battle against an antitrust fine after a top adviser to the European Union's highest court backed a 4.12 billion-euro ($4.74 billion) penalty imposed by EU antitrust regulators over how the tech giant imposes contractual obligations on device manufacturers deploying its Android operating system.
Juliane Kokott, an advocate general of the European Union's Court of Justice in Luxembourg, said Google is wrong to attempt to challenge the fine. She said the company for years held a dominant position in several markets of the Android system that enabled it to benefit from ensuring that users used its services like Google Search. Kokott recommended that judges should uphold the fine, according to a court press release.
The Biggest Companies Across America Are Cutting Their Workforces
Microsoft Plans to Cut Thousands More Employees
All the Hollywood Action Is Happening Everywhere But Hollywood
The Fed Waits Out the Tariff Economy
The Path to Record Deficits
A Google spokesperson said the company was disappointed by the opinion. If the court were to follow it, it could discourage investment in open platforms and ultimately harm users, developers and business partners, the spokesperson said.
The opinion is a blow for the search giant, which has for years tried to rid itself of multibillion-dollar penalties the commission has levied for antitrust violations. Judges don't have to follow the advocate general's opinion, but they often do.
The European Commission fined Google a record 4.34 billion euros ($4.98 billion) in 2018, alleging that the company unfairly used its dominance in the digital economy to compel device manufacturers and network operators to prioritize Google's own search engine traffic on Android devices.
Google first appealed that fine at the EU's general court, where judges in the lower tribunal largely upheld the commission's verdict but trimmed the original penalty to 4.12 billion euros.
Although Google's lawyers also argued that the lowered penalty still went too far, Kokott said the judges' fine calculation wasn't excessive to the point of being disproportionate, according to the full text of the opinion.
The company has made changes aimed at giving users more control over which search engines and browsers they set as default on their phones. Google in 2019 offered to let rivals appear on a choice screen.
The tech giant is now also bound by strict new rules under the EU's Digital Markets Act that govern how it and other large tech groups must treat smaller businesses that rely on their popular platforms such as search and Chrome to reach customers. Companies can be fined up to 10% of their annual worldwide turnover for flouting the rules, with penalties rising to 20% for repeat offences.
Google has racked up some 8.25 billion euros of EU competition fines in the last decade. Last year, it failed to cancel a 2.4 billion-euro penalty handed to it over how its shopping search results position other results from competing price-comparison sites.
Write to Edith Hancock at edith.hancock@wsj.com
Fed Holds Rates Steady and Keeps Door Open to Cuts
Stablecoin Legislation Will Juice Demand for Treasurys—to a Point
Waymo Wants to Bring Its Robotaxis to New York City
QXO Proposes $5 Billion Acquisition of GMS
What UnitedHealth Can Do to Revive Its Battered Stock

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

2 hours ago

• Yahoo

Why IBM Is the Best Quantum Computing Stock to Buy Right Now

IBM is a quantum computing pioneer. The company expects to reach true quantum advantage by 2026 and have a large fault-tolerant system in place by 2029. With a long track record and a clear roadmap, IBM is emerging as a quantum computing leader. 10 stocks we like better than International Business Machines › A future quantum computer could potentially solve problems that are essentially impossible for even the most powerful supercomputer. The magic comes from the nature of quantum physics. While traditional computers operate on bits that can be in only one of two states, a quantum qubit is probabilistic, occupying some combination of those two states. This property opens the door to exponentially faster computations. Today's quantum computers generally aren't capable of solving real-world problems quicker than traditional computers. They are capable of performing some types of computations faster, but these computations are more toy problems than anything else. When Alphabet's Google unveiled its Willow quantum chip last year, it claimed that Willow could perform a particular benchmark in five minutes that would take a supercomputer 10 septillion years. Unfortunately, that benchmark has no known real-world applications. Another problem is error correction. Qubits are fragile, and errors are inevitably introduced over the course of a computation. Those errors must be prevented, corrected, or otherwise mitigated for long enough for a computation to be completed. Microsoft made some noise on this front earlier this year with its Majorana 1 quantum chip, which uses exotic particles to create more robust qubits. However, the company is in the early stages of scaling this technology, and it could very well be many years before anything useful comes out of it. International Business Machines (NYSE: IBM), a quantum computing pioneer, now sees a path to full-scale quantum error correction by 2029 and true quantum advantage by the end of 2026. The company has a clear roadmap, and if it can deliver, quantum computing could turn into a major business for the century-old tech giant. IBM is taking a modular approach on its path to the holy grail of quantum computing. This year, IBM will release Nighthawk, its new quantum process with 120 qubits and 5,000 quantum gates. Over the next few years, successive versions of Nighthawk will increase the number of gates, culminating in 2028 with a 15,000-gate version that can be linked together in groups of nine. IBM believes Nighthawk will be able to achieve true quantum advantage. Nighthawk is a stepping stone toward Starling, the fault-tolerant quantum computer planned for 2028. To build Starling, IBM will release three iterations of quantum chips over the next few years that include the necessary technology to make Starling a reality. IBM Quantum Loon comes this year, featuring greater connectivity than the company's current quantum chips. IBM Quantum Kookaburra comes in 2026, bringing the ability to store information and process it with an attached processing unit. And IBM Quantum Cockatoo is set for 2027, allowing entanglement between modules. Starling, which will feature 200 logical qubits and 100 million quantum gates, will be built in 2028 and deliver fault-tolerance by 2029, according to IBM's roadmap. Plenty of companies are racing toward viable quantum computing, but IBM has two things that make it unique: a decades-long track record researching and building quantum computers, and a clear roadmap to reach fault-tolerance and true quantum advantage. While it's impossible to predict how large of an opportunity quantum computing could be for IBM, one estimate puts the economic value generated by quantum computing at $850 billion by 2040, with the market for quantum hardware and software potentially worth $170 billion. If IBM can truly pull ahead of its rivals and deliver real-world results with its quantum computers by the end of the decade, it will be in a great position to reap the rewards of the quantum computing revolution. IBM's valuation today looks reasonable considering the enormous potential of quantum computing. Based on the company's outlook for 2025, IBM stock trades for roughly 19 times free cash flow. While the stock isn't as cheap as it was a few years ago, IBM still looks like a solid buy. The company's hybrid cloud and artificial intelligence (AI) businesses are driving growth today, and quantum computing has the potential to drive growth in the 2030s and beyond. Before you buy stock in International Business Machines, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and International Business Machines wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $658,297!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $883,386!* Now, it's worth noting Stock Advisor's total average return is 992% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Timothy Green has positions in International Business Machines. The Motley Fool has positions in and recommends Alphabet, International Business Machines, and Microsoft. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Why IBM Is the Best Quantum Computing Stock to Buy Right Now was originally published by The Motley Fool Sign in to access your portfolio

Yahoo

4 hours ago

• Yahoo

HER2-low Cancers Market Set to Register Immense Growth at a CAGR of 9.4% During the Study Period (2020-2034)

The future of the HER2-low cancer treatment market is poised for significant transformation, driven by the approval of ENHERTU and the advancement of other innovative antibody-drug conjugates (ADCs) like DATROWAY, TRODELVY, ifinatamab deruxtecan, BB-1701, and Disitamab vedotin. These ADCs are designed to target HER2-low-expressing cancer cells, with major development ongoing in Breast Cancer. LAS VEGAS, June 19, 2025 /PRNewswire/ -- DelveInsight's HER2-low Cancers Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, emerging HER2-low cancer therapies, market share of individual therapies, and current and forecasted HER2-low cancers market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the HER2-low Cancers Market Report HER2-low cancer refers to tumors with low HER2 protein expression that do not meet the criteria for HER2-positive classification. The prevalence of HER2-low expression varies across cancers, occurring in approximately 63% of breast cancers, 42% of biliary tract cancers, 38% of urothelial carcinomas, and 35% of gastric cancers. As per DelveInsight's analysis, the total market size of HER2-low cancers in the 7MM was USD 3.2 billion in 2024 and is projected to grow during the forecast period (2025-2034), driven by ENHERTU's usage and strong uptake in this cancer type. Of the target indications, breast cancer and gastric cancer are anticipated to generate the most revenue by 2034 due to the highest level of clinical development and authorization of HER2-low cancer therapies. Among all therapies, ENHERTU is expected to capture the highest market share, due to its proven clinical efficacy, strong safety, and first-mover advantage in treating HER2-low cancers. Based on Delveinsight's assessment in 2024, the 7MM had approximately 360,000 target pool cases of HER2-low cancers. These cases are projected to increase during the forecast period (2025–2034) due to recent clinical advances recognizing HER2-low as a distinct category, thereby expanding the treatable patient population There are no HER2-targeting therapies currently in the pipeline for first-line treatment; all available options are focused on the relapsed or refractory setting. The HER2-low breast cancer pipeline is becoming increasingly competitive, as ENHERTU has dramatically shifted market dynamics. Its approval for HER2-low breast cancer has significantly transformed the market trajectory, leading to a doubling of overall sales in 2023. Leading HER2-low cancer companies, such as AstraZeneca, Daiichi Sankyo, RemeGen, Pfizer (Seagen), Gilead Sciences, Merck, Bliss Biopharmaceutical (Hangzhou), Zymeworks, Jazz Pharmaceuticals, ALX Oncology, Dragonfly Therapeutics, Mersana Therapeutics, and others, are developing novel HER2-low cancer therapies that can be available in the HER2-low cancer market in the coming years. Some of the key HER2-low cancer therapies in the pipeline include DATROWAY (datopotamab deruxtecan/Dato-DXd), AIDIXI (disitamab vedotin), TRODELVY (sacituzumab govitecan), Ifinatamab deruxtecan (I-DXd)/MK-2400, BB-1701, ZIIHERA (zanidatamab), DF1001, Emiltatug ledadotin (XMT-1660), and others. Discover which therapies are expected to grab the HER2-low cancers market share @ HER2-low Cancers Market Report HER2-low Cancers Market Dynamics The HER2-low cancer market has recently garnered significant attention, primarily due to the advancements in targeted therapies for cancers with low expression of the HER2 protein. While HER2-positive cancers, such as breast and gastric cancers, have long been the focus of targeted treatments like trastuzumab (HERCEPTIN), HER2-low cancers represent a distinct subset that requires different therapeutic strategies. These cancers exhibit a lower level of HER2 expression, making them more challenging to treat with traditional HER2-targeted therapies. However, recent breakthroughs in ADCs and novel monoclonal antibodies are starting to offer new avenues for patients with this subgroup. As researchers continue to explore HER2-low cancers, one of the key dynamics driving the market is the recognition that these tumors can benefit from a broader range of treatments. In particular, ADCs are showing promise as they allow for more precise delivery of chemotherapy agents directly to tumor cells. This approach offers hope for patients whose cancers were previously thought to be less amenable to targeted therapies. The approval of drugs like ENHERTU for HER2-low breast cancer has created a significant shift in the oncology treatment landscape, leading to a surge of interest from pharmaceutical companies developing similar therapies. The growing understanding of HER2-low cancers has also influenced diagnostic practices, with an emphasis on accurate biomarker testing. Companies are now focusing on developing more sensitive and specific assays to detect low levels of HER2 expression, ensuring that patients are correctly identified for targeted treatment options. This has led to the rise of precision medicine in oncology, where treatments are tailored not only to the type of cancer but also to the molecular characteristics of the tumor. The better the diagnostics, the more likely it is that patients will receive appropriate therapies, boosting market potential. Additionally, market dynamics are shaped by the competitive landscape, with several big pharmaceutical companies investing heavily in the development of new agents for HER2-low cancers. The approval of HER2-targeted treatments for low-expressing cancers is expected to trigger a surge in demand, especially in indications such as breast and gastric cancers. However, challenges remain, including the cost of these novel therapies, their accessibility in different healthcare settings, and the need for continued clinical validation. As these therapies advance through the pipeline, the future market for HER2-low cancer treatments looks promising, but it will require a combination of scientific innovation, regulatory support, and healthcare infrastructure to realize its full potential. HER2-low Cancers Treatment Market HER2-low cancers, which are marked by low levels of the HER2 protein, pose distinct treatment challenges. Recent research has focused on targeted therapies for such cancers, especially breast cancers. Treatment options for HER2-low cancers, including gastric, endometrial, and other cancers, are evolving as research continues to explore the role of HER2 in these diseases. Traditional therapies, such as monoclonal antibodies and small molecular Tyrosine Kinase Inhibitors (TKIs), have shown limited effectiveness in breast cancers with HER2-low expression. For years, HER2-low breast cancer has been treated similarly to HER2-negative breast cancer, including HR+/HER2− and TNBC cases. For gastric cancer, particularly adenocarcinoma of the stomach and gastroesophageal junction, recent research has highlighted the potential of ENHERTU, an antibody-drug conjugate. ENHERTU has shown promising results in patients with HER2-low expression (IHC 1+ or 2+/ISH−). In January 2025, ENHERTU was approved by the US FDA for treating adult patients with unresectable or metastatic HR-positive, HER2-low, or HER2-ultralow (IHC 0 with membrane staining) breast cancer, who have progressed on one or more endocrine therapies in the metastatic setting, based on an FDA-approved test. For HR-negative/HER2-low breast cancer, treatment usually begins with first-line chemotherapy, potentially combined with immunotherapy for PD-L1-positive patients, followed by sequential chemotherapy treatments. For HR-positive breast cancer, due to its progression-free survival advantage over chemotherapy, PARP inhibitors (PARPi) are considered for patients with a germline BRCA mutation. Learn more about the FDA-approved HER2-low cancer therapies @ HER2-low Cancer Treatment Drugs HER2-low Cancers Pipeline Therapies and Key Companies Currently, the clinical development landscape includes late and mid-stage assets. Consequently, our forecast considers the potential impact of Pfizer's Disitamab vedotin, Immutep's Eftilagimod alpha (IMP321), AstraZeneca and Daiichi Sankyo's DATROWAY, Gilead Sciences' TRODELVY, Duality Biologics and BioNTech's DB-1303/BNT323, Daiichi Sankyo and Merck's Ifinatamab deruxtecan, Bliss Biopharmaceutical's BB-1701, and Dragonfly Therapeutics' DF1001. Dato-DXd is an experimental TROP2-targeted ADC, developed using Daiichi Sankyo's proprietary DXd ADC Technology. It is one of six DXd ADCs in their oncology pipeline and a key program in AstraZeneca's ADC scientific platform. In collaboration with Sapporo Medical University, Dato-DXd is designed with topoisomerase I inhibitor payloads linked via tetrapeptide-based cleavable linkers. The drug is currently in Phase III trials for inoperable or metastatic HR-positive, HER2-low or negative breast cancer (IHC 0, IHC 1+, or IHC 2+/ISH-) that has previously been treated with endocrine therapy and at least one systemic therapy. AstraZeneca expects Phase I results from the TROPION-PanTumor01 trial (NCT03401385) to be available in the latter half of 2025, as reported in their 2024 clinical trial appendix. In February 2025, Daiichi Sankyo presented data from the Phase III TROPION-Breast01 DATROWAY trial for HR+/HER2-low breast cancer at the ESMO Virtual Meeting. While overall survival did not reach statistical significance, Dato-DXd showed a manageable safety profile and continued to favor the investigator's choice of chemotherapy on secondary efficacy endpoints. TRODELVY is a first-in-class TROP-2-targeting ADC designed with a proprietary hydrolyzable linker and SN-38, a topoisomerase I inhibitor payload. This combination delivers potent activity to TROP-2-expressing cells and the surrounding microenvironment. It is currently undergoing Phase III trials for HR-positive/HER-negative (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH–]) inoperable, locally advanced, or metastatic breast cancer after endocrine therapy. Its patent is set to expire in the US by 2028 and in Europe by 2029. BNT323/DB-1303 is a third-generation ADC targeting HER2, built on DualityBio's proprietary Duality Immune Toxin Antibody Conjugates (DITAC) platform. This candidate has shown antitumor activity in HER2-positive and HER2-low tumor models, as well as in multiple solid tumors, including breast, gastric, endometrial, biliary tract cancers, and other advanced solid tumors. BNT323/DB-1303 is currently being evaluated in a Phase I/II study (NCT05150691) for advanced/metastatic solid tumors and in a pivotal Phase III study (NCT06018337) for HR-positive and HER2-low, metastatic breast cancer that has progressed on hormone and/or CDK4/6 therapy. The anticipated launch of these emerging therapies are poised to transform the HER2-low cancers market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the HER2-low cancers market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about HER2-low cancer drug clinical trials, visit @ HER2-low Cancer Drugs Recent Developments in the HER2-low Cancer Market In January 2025, the US FDA approved ENHERTU for adults with unresectable or metastatic HR+, HER2-low or HER2-ultralow breast cancer, based on DESTINY-Breast06 Phase III results following progression on one or more endocrine therapies. In January 2025, the US FDA granted FTD to emiltatug ledadotin, B7-H4 ADC, for advanced or metastatic HER2-low or HER2-negative breast cancer, including triple-negative cases previously treated with a topoisomerase-1 inhibitor ADC, based on promising results from a Phase I trial. As per BioNTech's Q4 2024 annual presentation, published in March 2025, the company plans to prioritize the advancement of DB-1303 for BLA submission in 2025 as a second-line or subsequent therapy in HER2-expressing advanced endometrial cancer. According to Pfizer's presentation, the launch of disitamab vedotin for second-line HER2+/low metastatic urothelial carcinoma is expected in 2026. HER2-low Cancers Overview HER2 is a transmembrane tyrosine kinase receptor encoded by the ERBB2 gene, playing a crucial role in cell growth, differentiation, and survival. It is part of the epidermal growth factor receptor family and is typically analyzed using molecular techniques. HER2 protein overexpression is assessed through immunohistochemistry (IHC), while gene amplification is determined using fluorescence in situ hybridization (FISH). A HER2-low status is defined as an IHC score of 1+ or 2+, with no gene amplification detected by FISH. HER2/neu primarily activates the MAPK and PI3K pathways, contributing to malignant transformation when overexpressed or amplified. This receptor is found in several cancers, including breast, colorectal, ovarian, endometrial, bladder, gastric, and biliary tract cancers, with breast cancer being the most prevalent. HER2-low Cancers Epidemiology Segmentation In the 7MM, in 2024, among all the HER2-low cancer indications, breast cancer accounted for the highest number of incident cases, while ovarian cancer occupied the bottom of the ladder. The HER2-low cancers market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Targeted Patient Pool of Selected Indications for HER2-low Cancers Treatment Eligible Pool of Selected Indications for HER2-low Cancers Total Incident Cases of HER2-low Breast Cancers Age-specific Cases of HER2-low Breast Cancers Stage-specific Cases of HER2-low Breast Cancers HER2-low Cancers Report Metrics Details Study Period 2020–2034 HER2-low Cancers Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] HER2-low Cancer Market CAGR 9.4 % HER2-low Cancer Market Size in 2024 USD 3.2 billion Key HER2-low Cancer Companies AstraZeneca, Daiichi Sankyo, RemeGen, Pfizer (Seagen), Gilead Sciences, Merck, Bliss Biopharmaceutical (Hangzhou), Zymeworks, Jazz Pharmaceuticals, ALX Oncology, Dragonfly Therapeutics, Mersana Therapeutics, and others Key HER2-low Cancer Therapies ENHERTU, DATROWAY (datopotamab deruxtecan/Dato-DXd), AIDIXI (disitamab vedotin), TRODELVY (sacituzumab govitecan), Ifinatamab deruxtecan (I-DXd)/MK-2400, BB-1701, ZIIHERA (zanidatamab), DF1001, Emiltatug ledadotin (XMT-1660), and others Scope of the HER2-low Cancers Market Report HER2-low Cancers Therapeutic Assessment: HER2-low Cancers current marketed and emerging therapies HER2-low Cancers Market Dynamics: Conjoint analysis of approved and emerging HER2-low Cancers Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Cost assumptions, HER2-low Cancers Market Access and Reimbursement Discover more about HER2-low cancer drugs in development @ HER2-low Cancers Clinical Trials Table of Contents 1 KEY INSIGHTS 2 REPORT INTRODUCTION 3 EXECUTIVE SUMMARY 4 KEY EVENTS 5 EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY 6 HER2-LOW CANCERS MARKET OVERVIEW AT A GLANCE 6.1 MARKET SHARE (%) DISTRIBUTION BY THERAPIES OF HER2-LOW CANCERS IN 2024 IN THE 7MM 6.2 MARKET SHARE (%) DISTRIBUTION BY THERAPIES OF HER2-LOW CANCERS IN 2034 IN THE 7MM 6.3 MARKET SHARE (%) DISTRIBUTION BY INDICATIONS IN 2024 IN THE 7MM 6.4 MARKET SHARE (%) DISTRIBUTION BY INDICATIONS IN 2034 IN THE 7MM 7 DISEASE BACKGROUND AND OVERVIEW 7.1 INTRODUCTION 7.2 SYMPTOMS 7.3 RISK FACTORS 7.4 PATHOPHYSIOLOGY OF HER2-LOW CANCERS 7.5 PROGNOSIS 7.6 DIAGNOSIS 7.7 TREATMENT 7.8 GUIDELINES 7.8.1 Diagnostic Guidelines and Recommendations for HER2-low Cancers 7.8.1.1 ASCO Diagnostic Recommendations for HER2 Testing 7.8.1.2 The ASCO-College of American Pathologists (CAP) Recommendations for HER2 Testing 7.8.1.3 ESCO Guidelines for HER2-low Cancers 7.8.1.4 Interpretation by the ASCO/CAP 2018 Guidelines and by the 2023 ESMO Consensus on HER2-low Breast Cancer Regarding Each Pattern of HER2 Staining 7.8.1.5 Pan-Asian Adapted ESMO Guidelines for HER2-low Cancers 7.8.1.6 Japanese Breast Cancer Society Clinical Practice Guidelines for Pathological Diagnosis of Breast Cancer, 2022 Edition 7.8.2 Treatment Guidelines and Recommendations for HER2-low Cancers 7.8.2.1 ESMO Guidelines for HER2-low Cancers 7.8.2.2 Pan-Asian Adapted ESMO Guidelines for HER2-low Cancers 8 EPIDEMIOLOGY AND PATIENT POPULATION 8.1 KEY FINDINGS 8.2 ASSUMPTION AND RATIONALE OF HER2-LOW CANCERS: THE 7MM 8.3 TOTAL TARGETED PATIENT POOL OF SELECTED INDICATIONS FOR HER2-LOW CANCERS IN THE 7MM 8.4 TREATMENT ELIGIBLE POOL OF SELECTED INDICATIONS FOR HER2-LOW CANCERS IN THE 7MM 8.5 THE UNITED STATES 8.5.1 Total Incident Cases of HER2-low Breast Cancers in the United States 8.5.2 Age-specific Cases of HER2-low Breast Cancers in the United States 8.5.3 Stage-specific Cases of HER2-low Breast Cancers in the United States 8.6 EU4 AND THE UK 8.6.1 Total Incident Cases of HER2-low Breast Cancers in EU4 and the UK 8.6.2 Age-specific Cases of HER2-low Breast Cancers in EU4 and the UK 8.6.3 Stage-specific Cases of HER2-low Breast Cancers in EU4 and the UK 8.7 JAPAN 8.7.1 Total Incident Cases of HER2-low Breast Cancers in Japan (2020-2034) 8.7.2 Age specific Cases of HER2-low Breast Cancers in Japan 8.7.3 Stage-specific Cases of HER2-low Breast Cancers in Japan 9 PATIENT JOURNEY 10 MARKETED DRUG 10.1 KEY COMPETITOR 10.2 ENHERTU (TRASTUZUMAB DERUXTECAN): DAIICHI SANKYO AND ASTRAZENECA 10.2.1 Product Description 10.2.2 Regulatory Milestones 10.2.3 Other Developmental Activities 10.2.4 Clinical Development 10.2.4.1 Clinical Trial Information 10.2.5 Safety and Efficacy 11 EMERGING THERAPIES 11.1 KEY CROSS COMPETITION 11.2 DATROWAY (DATOPOTAMAB DERUXTECAN/DATO-DXD): ASTRAZENECA AND DAIICHI SANKYO 11.2.1 Product Description 11.2.2 Other Developmental Activities 11.2.3 Clinical Development 11.2.3.1 Clinical Trials Information 11.2.4 Safety and Efficacy 11.2.5 Analyst Views 11.3 TRODELVY (SACITUZUMAB GOVITECAN): GILEAD SCIENCES 11.3.1 Product Description 11.3.2 Other Developmental Activities 11.3.3 Clinical Development 11.3.3.1 Clinical Trials Information 11.3.4 Safety and Efficacy 11.3.5 Analyst Views 11.4 DB-1303/BNT323 (TRASTUZUMAB PAMIRTECAN): DUALITY BIOLOGICS AND BIONTECH 11.4.1 Product Description 11.4.2 Other Developmental Activities 11.4.3 Clinical Development 11.4.3.1 Clinical Trials Information 11.4.4 Safety and Efficacy 11.4.5 Analyst Views 11.5 AIDIXI (DISITAMAB VEDOTIN): REMEGEN AND PFIZER (SEAGEN) 11.5.1 Product Description 11.5.2 Other Developmental Activities 11.5.3 Clinical Development 11.5.4 Safety and Efficacy 11.5.5 Analyst Views 11.6 EFTILAGIMOD ALPHA (IMP321): IMMUTEP 11.6.1 Product Description 11.6.2 Other Developmental Activities 11.6.3 Clinical Development 11.6.3.1 Clinical Trials Information 11.6.4 Safety and Efficacy 11.6.5 Analyst Views 11.7 IFINATAMAB DERUXTECAN (I-DXD)/MK-2400: DAIICHI SANKYO AND MERCK 11.7.1 Product Description 11.7.2 Other Developmental Activities 11.7.3 Clinical Development 11.7.3.1 Clinical Trials Information 11.7.4 Analyst Views 11.8 BB-1701: BLISS BIOPHARMACEUTICAL (HANGZHOU) 11.8.1 Product Description 11.8.2 Other Developmental Activities 11.8.3 Clinical Development 11.8.3.1 Clinical Trials Information 11.8.4 Safety and Efficacy 11.8.5 Analyst Views 11.9 DF1001: DRAGONFLY THERAPEUTICS 11.9.1 Product Description 11.9.2 Other Developmental Activities 11.9.3 Clinical Development 11.9.3.1 Clinical Trials Information 11.9.4 Safety and Efficacy 11.9.5 Analyst Views 11.1 ZIIHERA (ZANIDATAMAB): ZYMEWORKS/JAZZ PHARMACEUTICALS/ALX ONCOLOGY 11.10.1 Product Description 11.10.2 Other Developmental Activities 11.10.3 Clinical Development 11.10.4 Safety and Efficacy 11.10.5 Analyst Views 11.11 HF158K1/HF-K1: HIGHFIELD BIOPHARMACEUTICALS 11.11.1 Product Description 11.11.2 Other Developmental Activities 11.11.3 Clinical Development 11.11.3.1 Clinical Trials Information 11.11.4 Safety and Efficacy 11.11.5 Analyst Views 11.12 EMILTATUG LEDADOTIN (XMT-1660): MERSANA THERAPEUTICS 11.12.1 Product Description 11.12.2 Other Developmental Activities 11.12.3 Clinical Development 11.12.3.1 Clinical Trials Information 11.12.4 Safety and Efficacy 11.12.5 Analyst Views 12 HER2-LOW CANCERS: SEVEN MAJOR MARKET ANALYSIS 12.1 KEY FINDINGS 12.2 MARKET OUTLOOK 12.3 CONJOINT ANALYSIS 12.4 KEY MARKET FORECAST ASSUMPTIONS 12.4.1 Cost Assumptions 12.4.2 Pricing Trends 12.4.3 Analogue Assessment 12.4.4 Launch Year and Therapy Uptakes 12.5 TOTAL MARKET SIZE OF HER2-LOW CANCERS BY COUNTRY IN THE 7MM 12.6 TOTAL MARKET SIZE OF HER2-LOW CANCERS BY INDICATIONS IN THE 7MM 12.7 MARKET SIZE OF HER2-LOW CANCERS BY THERAPIES IN 7MM 12.8 UNITED STATES MARKET SIZE 12.8.1 Total Market Size of HER2-low Cancers in the United States 12.8.2 Market Size of HER2-low Cancers by Therapies in the United States 12.9 EU4 AND THE UK MARKET SIZE 12.9.1 Total Market Size of HER2-low Cancers in EU4 and the UK 12.9.2 Market Size of HER2-low Cancers by Therapies in EU4 and the UK 12.1 JAPAN 12.10.1 Total Market Size of HER2-low Cancers in Japan 12.10.2 Market Size of HER2-low Cancers by Therapies in Japan 13 UNMET NEEDS 14 SWOT ANALYSIS 15 KOL VIEWS 16 MARKET ACCESS AND REIMBURSEMENT 16.1 UNITED STATES 16.1.1 Centre for Medicare and Medicaid Services (CMS) 16.2 EU4 AND THE UK 16.2.1 Germany 16.2.2 France 16.2.3 Italy 16.2.4 Spain 16.2.5 United Kingdom 16.3 JAPAN 16.3.1 MHLW 16.4 MARKET ACCESS AND REIMBURSEMENT OF HER2-LOW CANCERS 17 APPENDIX 17.1 BIBLIOGRAPHY 17.2 REPORT METHODOLOGY 18 DELVEINSIGHT CAPABILITIES 19 DISCLAIMER 20 ABOUT DELVEINSIGHT Related Reports HER2+ Market HER2+ Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report deliver an in-depth understanding of HER2+, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HER2+ companies, including Zymeworks, Jazz Pharmaceuticals, Ambrx, AnBogen Therapeutics, Enliven Therapeutics, Roche, among others. Metastatic HER2-Positive Breast Cancer Market Metastatic HER2-Positive Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic HER2-positive breast cancer companies, including Byondis, Roche, Ambrx, Zymeworks, Jazz Pharmaceuticals, Pfizer, among others. Metastatic HR+/HER2-negativeBreast Cancer Market Metastatic HR+/HER2− Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic HR+/HER2-negative breast cancer companies including Merck, Arvinas, Olema Pharmaceuticals, Celcuity, Roche, AstraZeneca, Daiichi Sankyo, Eli Lilly, Sermonix Pharmaceuticals, Genentech, Veru Pharma, DualityBio, BioNtech, Evgen Pharma, Carrick Therapeutics, EQRx, G1 Therapeutics, Immutep, among others. Triple Negative Breast Cancer Market Triple Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key TNBC companies including AstraZeneca, Daiichi Sankyo, OBI Pharma, Astellas Pharma, Pfizer, Galera Therapeutics, BioNTech, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

The Hill

5 hours ago

• The Hill

Spain asks for break on NATO contribution: Report

Leaders in Madrid urged NATO Secretary-General Mark Rutte to exempt them from a proposed defense spending goal set at 5 percent of gross domestic product (GDP) ahead of next week's summit at The Hague. 'Committing to a 5% target would not only be unreasonable, but also counterproductive, as it would move Spain further away from optimal spending and would hinder the EU's ongoing efforts to strengthen its security and defence ecosystem,' Prime Minister Pedro Sánchez wrote in a letter to Rutte, according to a copy reviewed by Reuters. 'It is the legitimate right of every government to decide whether or not they are willing to make those sacrifices. As a sovereign Ally, we choose not to,' he added. Spain currently has the lowest military spending among member nations, devoting 1.3 percent of its GDP to defense spending last year, according to reports from Politico EU. Member nations agreed to commit 2 percent of their GDP to defense spending in 2014, with the hope of ensuring NATO can sustain continued military readiness. The Russia-Ukraine conflict has sparked concerns about the possibility of a wider war involving Europe amid Russian President Vladimir Putin's push to obtain more land. However, Spain said the Kremlin poses no current threat to its borders but did not oppose heightened security for other NATO member nations. 'Of course, it is not our intention to limit the spending ambitions of other allies or to obstruct the outcome of the upcoming summit,' Sanchez wrote in the letter. Rutte has suggested that an increase in defense spending levels should ensure that 3.5 percent of GDP is allocated to military expenditures, while 1.5 percent is allocated for defense-related items, such as military mobility and cybersecurity, Politico EU reported. However, Sanchez said the policy would force Spain to purchase off-the-shelf equipment instead of cultivating its own industrial base as recorded in his letter. President Trump has encouraged Rutte's push for growth, citing a mounting concern for the United States' dominant support of the war in Ukraine, a non-member nation designated as a NATO partner country. Although his administration signed a minerals agreement with the country to recoup the financial commitment seeped in weapons packages and the purchase of military equipment, the president has urged other nations to help back the Eastern European ally. 'I didn't see Spain's comments, I'll make sure the president sees them and I can assure you he wants to see all European countries pay their fair share and meet that 5 percent threshold,' White House press secretary Karoline Leavitt said during Thursday's press briefing. 'It's only fair considering the American taxpayers have given a significant chunk of money to the tune of billions of dollars to support our mutual interests and our assured defense.' The NATO summit is set to take place from June 24-25 and would require all 32 member nations to approve the increase in defense spending to solidify the objective. 'The NATO Summit is coming at a very precarious moment for the transatlantic relationship, marked by uncertainty about the US commitment to Europe, a relative stalemate in peace negotiations between Russia, and Ukraine and ongoing tensions over transatlantic trade,' Lauren Speranza, a fellow at the Center for European Progress said in a statement. 'As the first NATO summit of President Trump's second term, I do think The meeting will offer us some insight into how the administration will approach the Alliance going forward, following some of the previous criticisms we've heard of NATO and calls for Europe to do more to take greater responsibility for its own defense.'